Assessment of the New 2012 EULAR/ACR Clinical Classification Criteria for Polymyalgia Rheumatica: A Prospective

Gulsen Ozen1, Nevsun Inanc1, Ali Ugur Unal1

  • 1From the Department of Rheumatology, and Department of Physical Therapy and Rehabilitation, Faculty of Medicine, Marmara University; Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Goztepe Medeniyet University; Department of Rheumatology, Fatih Sultan Mehmet Education and Research Hospital; Department of Rheumatology, Faculty of Medicine, Bilim University, Istanbul; Department of Rheumatology, Faculty of Medicine, Gaziantep University, Gaziantep; Department of Rheumatology, Faculty of Medicine, Pamukkale University, Denizli; Department of Rheumatology, Sakarya Education and Research Hospital, Sakarya; Department of Rheumatology, Suleyman Demirel University, Isparta; Department of Rheumatology, Faculty of Medicine, Cumhuriyet University, Sivas; Department of Rheumatology, Faculty of Medicine, Erciyes University, Kayseri; Department of Rheumatology, Faculty of Medicine, Trakya University, Edirne; Department of Rheumatology, Selcuklu Faculty of Medicine, Selcuk University, Konya; Department of Rheumatology, Faculty of Medicine, Ege University, Izmir; Department of Rheumatology, Faculty of Medicine, Ondokuz Mayis University, Samsun; Department of Rheumatology, Faculty of Medicine, Sutcu Imam University, Kahramanmaras; Department of Rheumatology, Yunus Emre Government Hospital, Eskisehir, Turkey; Department of Rheumatology, School of Medicine, University of Ottawa, Ottawa, Ontario, Canada.G. Ozen, MD, Department of Rheumatology, Faculty of Medicine, Marmara University; N. Inanc, MD, Professor, Department of Rheumatology, Faculty of Medicine, Marmara University; A.U. Unal, MD, Department of Rheumatology, Faculty of Medicine, Marmara University; S. Bas, MD, Department of Rheumatology, Faculty of Medicine, Marmara University; G. Kimyon, MD, Department of Rheumatology, Faculty of Medicine, Gaziantep University; B. Kisacik, MD, Professor, Department of Rheumatology, Faculty of Medicine, Gaziantep University; A.M. Onat, MD, Professor, Department of Rhe

Abstract

Insights

The new 2012 European League Against Rheumatism/American College of Rheumatology criteria for polymyalgia rheumatica (PMR) show high sensitivity but need improvement in specificity, particularly for distinguishing PMR from seronegative rheumatoid arthritis (RA). Further modifications may enhance diagnostic accuracy.

Area of Science:

  • Rheumatology
  • Clinical Classification
  • Diagnostic Criteria

Background:

  • Polymyalgia rheumatica (PMR) diagnosis can be challenging due to overlapping symptoms with other conditions.
  • Existing diagnostic criteria require evaluation against newer classification systems.

Purpose of the Study:

  • To compare the performance of the 2012 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) PMR classification criteria against previous criteria.
  • To assess the ability of the new criteria to differentiate PMR from mimicking conditions in a multicenter prospective study.

Main Methods:

  • A prospective, multicenter study evaluated patients over 50 with new-onset bilateral shoulder pain and elevated acute-phase reactants (APR).
  • Patients were assessed using both the 2012 EULAR/ACR criteria and previous diagnostic criteria.
  • Discriminating capacity, sensitivity, and specificity were calculated after a 1-year follow-up, with 133 diagnosed with PMR and 142 with non-PMR conditions (including RA).

Main Results:

  • The 2012 EULAR/ACR criteria demonstrated good discriminating capacity (AUC 0.736 for non-PMR, 0.781 for RA) and high sensitivity (89.5%).
  • Specificity was 57.7% against all non-PMR cases and varied significantly against specific conditions (e.g., 20.7% for seronegative RA).
  • Previous criteria, except Bird criteria, generally showed lower sensitivity but higher specificity compared to the new criteria.

Conclusions:

  • The 2012 EULAR/ACR criteria are highly sensitive for diagnosing PMR.
  • However, their specificity is insufficient for differentiating PMR from other inflammatory and noninflammatory shoulder conditions, especially seronegative RA.
  • Enhancements like incorporating imaging or adjusting APR cutoff values may improve the specificity of these criteria.

Related Concept Videos

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
1.0K
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
790
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
487
Pericarditis II: Clinical Features and Diagnostic Tests01:19

Pericarditis II: Clinical Features and Diagnostic Tests

Pericarditis is distinguished by inflammation of the pericardium, the fibrous sac that encases the heart. It can be acute, lasting less than six weeks, or chronic, persisting for over three months. Understanding its clinical manifestations and diagnostic findings is crucial for timely and effective management.Clinical ManifestationsWhile pericarditis can be asymptomatic, it usually presents with characteristic symptoms such as:Chest Pain: The most characteristic symptom of pericarditis is chest...
519
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
441
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
450